18F-FDG PET in candidates for radiation therapy: Is it important and how do we validate its impact?

Journal of Nuclear Medicine

Volumn 44, Issue 1, 2003, Pages 30-32

  Hicks, Rodney J ^a   Mac Manus, Michael P ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NOTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT PLANNING; UTERINE CERVIX CANCER; VALIDATION PROCESS; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METHODOLOGY; NEOPLASM; PATIENT CARE; PATIENT SELECTION; PREDICTION AND FORECASTING; RADIOTHERAPY; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; PATIENT CARE MANAGEMENT; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RADIOTHERAPY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037207879     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (23)

1. Komaki R, Scott C, Ettinger D, et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys. 1997;38:149-155.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 1995;311:899-909.
3. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265-271.
4. Rischin D, Corry J, Smith J, et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol. 2002;20:1845-1852.
5. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593-1598.
6. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2001:CD002225.
7. Gaspar LE. Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cancer. Curr Opin Oncol. 2001;13:110-115.
8. Burman C, Chui CS, Kutcher G, et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997;39:863-873.
9. Van den Berge DL, Ridder MD, Storme GA. Imaging in radiotherapy. Eur J Radiol. 2000;36:41-48.
10. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551-560.
11. Macklis R, Weinhous M, Hamisch G. Intensity-modulated radiotherapy: rethinking basic treatment planning paradigms. Int J Radiat Oncol Biol Phys. 2000;48:317-318.
12. 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med. 2003;44:24-29.
13. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.
14. Scott IA, Greenberg PB, Phillips PA. The value of evidence-based medicine to consultant physicians. Aust NZ J Med. 2000;30:683-692.
15. Valk PE. Randomized controlled trials are not appropriate for imaging technology evaluation. J Nucl Med. 2000;41:1125-1126.
16. Steinert HC, Hauser M, Allemann F, et al. Nonsmall cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node sampling. Radiology. 1997;202:441-446.
17. Pieterman RM, van Puten JWG, Meuzler JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-261.
18. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 1994;191:371-377.
19. Vansteenkiste JF, De Leyn PR, Verschakelen JA, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable nonsmall cell lung cancer: a prospective analysis of 50 cases. Chest. 1997;112:1480-1486.
20. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-1604.
21. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 2001;92:886-895.
22. Mac Manus MP, Wong K, Hicks RJ, et al. Early mortality following radical radiotherapy (RRT) for non-small cell lung cancer (NSCLC): comparison of PET-staged and conventionally-staged cohorts treated at a large tertiary-referral center. Int J Radiat Oncol Biol Phys. 2002;52:351-361.
23. Mac Manus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:287-293.